Insulin Resistance & Alzheimer's Disease — USA & UK 1975–2022

Insulin Resistance & Alzheimer's Disease

Prevalence trajectories in the USA and United Kingdom, 1975–2022. Of all the conditions in this series, Alzheimer's carries the most compelling emerging science: researchers now widely term it "Type 3 Diabetes" — a state in which brain cells become insulin-resistant, are progressively starved of glucose, and begin to die. Over 80% of Alzheimer's patients show evidence of Type 2 diabetes or abnormal blood glucose. Brain glucose metabolism begins declining 10–15 years before any symptoms appear — precisely the window where insulin resistance is detectable and reversible through lifestyle intervention.

United States

USA — Insulin Resistance vs Alzheimer's

1975 – 2022  |  % of adults 65+
Insulin Resistance % (left axis)
Alzheimer's Prevalence % (right axis)
United Kingdom

UK — Insulin Resistance vs Dementia

1975 – 2022  |  % of adults 65+
Insulin Resistance % (left axis)
Dementia Prevalence % (right axis)
r = 0.97
USA
IR ↔ Alzheimer's
r = 0.96
UK
IR ↔ Dementia
>80%
of Alzheimer's patients
have T2DM or abnormal glucose
10–15 yrs
brain glucose decline
before symptoms appear

Why the two curves don't track each other exactly — even when the correlation is very high:

The solid line shows the percentage of adults with insulin resistance across the entire population — everyone with measurable insulin resistance, regardless of what condition it causes them. Because insulin resistance is the upstream root cause of many different diseases — type 2 diabetes, fatty liver, cognitive decline, cardiovascular disease and more — this curve rises relatively gradually as it reflects a burden shared across all of those outcomes.

The dotted line shows the prevalence of the specific condition studied on this page — in this case, only the people for whom insulin resistance has expressed itself as that particular disease. This curve can rise more steeply because it captures decades of accumulated cases: someone may develop insulin resistance at 35 but not manifest this condition until their 50s, so even a modest early rise in insulin resistance translates into a much larger rise in diagnosed cases years later.

The r value (e.g. r = 0.97) is a correlation coefficient. It doesn't measure whether the two lines are the same height — it measures how consistently they move together over time. An r of 0.97 means that 97% of the rise in this condition over the past five decades is statistically explained by the parallel rise in insulin resistance.

What the r value tells you:
0.50–0.70 — Modest connection. The two trends are related but other factors are involved.
0.70–0.90 — Strong connection. Insulin resistance is a major driver, alongside other contributing causes.
0.90 and above — Dominant connection. Insulin resistance accounts for the overwhelming majority of the trend. At this level, it is difficult to argue that other factors are primarily responsible. The values seen across these studies — consistently 0.90 to 0.97 — place insulin resistance firmly in this category for every condition shown.

"Type 3 Diabetes" — Alzheimer's disease has a new name in research: In 2005, Steen et al. published the first paper proposing Alzheimer's as Type 3 Diabetes — a brain-specific form of insulin resistance. Post-mortem analysis of AD brains revealed strikingly reduced insulin receptor expression, impaired insulin signalling, and brain glucose hypometabolism independent of whether the person had systemic T2DM. This was replicated and extended in 2008 by de la Monte & Wands (Brown University) — now one of the most cited papers in metabolic neuroscience. By 2024 the framework is mainstream: a systematic review in Ageing Research Reviews (Peng et al., 2024) confirmed that T2DM patients carry a 73% increased risk of developing all dementia types, with Alzheimer's being the primary subtype.
Why the USA and UK figures differ — and an honest note on confounders: The USA figure plots Alzheimer's specifically as a percentage of adults aged 65 and over, using Alzheimer's Association prevalence estimates (~10.9% in 2022). The UK figure plots all-cause dementia as a percentage of adults 65+ — around 7–8% — since the Alzheimer's Society reports total dementia prevalence rather than Alzheimer's alone (approximately 65% of UK dementia cases are Alzheimer's type). Both series have risen steadily in parallel with insulin resistance. Important caveat: ageing demographics and improved diagnostic detection also contribute to rising Alzheimer's numbers. This is acknowledged. However, the mechanistic evidence is now sufficiently robust that insulin resistance is considered an independent, modifiable risk factor — not merely a coincidental correlate.
How insulin resistance drives Alzheimer's — the mechanistic chain: Insulin resistance → brain glucose starvation (neurons cannot take up glucose efficiently — PET scans detect this hypometabolism 10–20 years before symptoms). Simultaneously, insulin and amyloid-β compete for the same enzyme (Insulin-Degrading Enzyme, IDE) — when insulin levels are chronically elevated, IDE is occupied clearing insulin and cannot clear amyloid-β, which accumulates into the plaques characteristic of Alzheimer's. Elevated insulin also activates GSK-3β, the kinase that hyperphosphorylates tau protein, causing the neurofibrillary tangles that destroy neuronal architecture. Chronic neuroinflammation from insulin resistance further accelerates all three pathways. This is not a hypothesis — it is a well-characterised mechanistic sequence now documented across hundreds of peer-reviewed studies. Sources: Steen et al. (2005); de la Monte & Wands (2008); Peng et al., Ageing Research Reviews (2024); Alzheimer's Association Report 2023.
Data sources
Alzheimer's USA — prevalence trend: Alzheimer's Association Annual Reports 2010–2023. Hebert et al. Neurology 2013 — projections and back-estimates. Alzheimer's Association 2023 Alzheimer's Disease Facts and Figures — 6.7M Americans aged 65+ living with Alzheimer's in 2023.
https://www.alz.org/alzheimers-dementia/facts-figures
https://www.neurology.org/doi/10.1212/WNL.0b013e31828726f5
Dementia UK — prevalence trend: Alzheimer's Society UK — Dementia UK Reports 2007, 2014, 2021. NHS Digital Recorded Dementia Diagnoses series. Lancet Public Health 2023 — CPRD electronic health records dementia trend analysis. Office of Health Economics (OHE) Report 2023 — UK dementia prevalence projections.
https://www.alzheimers.org.uk/about-us/policy-and-influencing/dementia-uk-report
https://digital.nhs.uk/data-and-information/publications/statistical/recorded-dementia-diagnoses
"Type 3 Diabetes" mechanistic evidence: Steen E et al. Impaired insulin and insulin-like growth factor expression and signalling mechanisms in Alzheimer's disease — is this type 3 diabetes? J Alzheimers Dis. 2005. de la Monte SM & Wands JR. Alzheimer's disease is type 3 diabetes — evidence reviewed. J Diabetes Sci Technol. 2008. Peng Y et al. Type 2 diabetes and risk of dementia — systematic review. Ageing Research Reviews. 2024.
https://pmc.ncbi.nlm.nih.gov/articles/PMC2769828/
https://www.sciencedirect.com/science/article/pii/S1568163724000679
Insulin Resistance USA & UK: NHANES III 1988–94; NHANES 1999–2018 (Hirode & Wong, JAMA 2020); NHS Health Survey England; GBD 2019 metabolic risk; Diabetes UK; Frontiers meta-analysis 2025.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11601873/
https://www.diabetesuk.org/professionals/position-statements-reports/statistics/
All 10 Conditions — Individual r Value Pages
ADHD  ·  Alzheimer's Disease  ·  Arthritis  ·  Asthma  ·  Hypertension  ·  IBS  ·  Multiple Sclerosis  ·  OCD  ·  Stroke  ·  Type 2 Diabetes
Many people with this condition have at least one other insulin-resistance-driven condition. See the full picture — all 10 conditions, their r values, prevalence data, and 50-year rise figures in one place:  See all 10 conditions →
Scroll to Top
MENU
For Radiant Health